(6S)-2-nitro-6-{3-[6-trifluoromethyl-3-pyridinyl]propoxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine | 1333170-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (6S)-2-nitro-6-{3-[6-trifluoromethyl-3-pyridinyl]propoxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
• 英文别名: (6S)-2-nitro-6-[3-[6-(trifluoromethyl)-3-pyridyl]propoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine；(6S)-2-nitro-6-[3-[6-(trifluoromethyl)pyridin-3-yl]propoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
• CAS: 1333170-22-1
• 化学式: C₁₅H₁₅F₃N₄O₄
• 分子量: 372.304
• InChiKey: FOIBGHSZTQYJCG-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  95
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  6-三氟甲基吡啶-3-醛 在 咪唑 、 lithium aluminium tetrahydride 、 5%-palladium/activated carbon 、 氢气 、 碘 、 sodium hydride 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 51.0h， 生成 (6S)-2-nitro-6-{3-[6-trifluoromethyl-3-pyridinyl]propoxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of Varied Ether Linker Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

  摘要：

  New analogues of antitubercular drug PA-824 were synthesized, featuring alternative side chain ether linkers of varying size and flexibility, seeking drug candidates with enhanced metabolic stability and high efficacy. Both alpha-methyl substitution and removal of the benzylic methylene were broadly tolerated in vitro, with a biaryl example of the latter class exhibiting an 8-fold better efficacy than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection and negligible fragmentation to an alcohol metabolite in liver microsomes. Extended linkers (notably propenyloxy, propynyloxy, and pentynyloxy) provided greater potencies against replicating M. tb (monoaryl analogues), with propynyl ethers being most effective under anaerobic (nonreplicating) conditions (mono/biaryl analogues). For benzyloxybenzyl and biaryl derivatives, aerobic activity was maximal with the original (OCH2) linker. One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model.

  DOI：

  10.1021/jm200377r